Mayo Clinic joins Biomerica’s InFoods Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy clinical trial

• Biomerica also announces its first Japanese patent has been granted for its InFoods IBS Diagnostic Guided Therapy technology

• InFoods Diagnostic-Guided Therapy is designed to identify patient-specific foods, that when removed from the diet, alleviate an individual's IBS symptoms
   
• Approximately 45 million Americans suffer from IBS¹

IRVINE, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced they have signed definitive agreements with Mayo Clinic to join the clinical trial for Biomerica’s new InFoods diagnostic-guided therapy (DGT), designed to alleviate Irritable Bowel Syndrome (IBS) symptoms.  Mayo Clinic is joining Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, Houston Methodist and the University of Michigan as primary enrollment centers for this study. Mayo Clinic can now begin enrollment of patients in this trial.

Biomerica has added several new, large medical centers and groups to assist with accelerating completion of the endpoint trial and to participate in the subsequent pivotal trial needed for final FDA clearance.  Biomerica continues to add leading gastrointestinal ("GI") physicians operating in world-renowned centers to the InFoods IBS clinical study, who are potential users and advocates for this product once cleared by the FDA.

Biomerica also announced today that the Japanese Patent Office has issued Biomerica’ s first Japanese patent pertaining to the Company’s InFoods family of products that allow for a revolutionary new treatment option for patients suffering from IBS and several other disease states.  Specifically, this patent  (JP,6681907,B) contains numerous claims that broadly cover a product that enables physicians to identify patient-specific foods (e.g. pork, milk, shrimp, broccoli, chickpeas, etc.), that when removed from the diet, may alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. It is estimated that about 19 million people in Japan suffer from IBS.

It is estimated that over 45 million Americans suffer from IBS and the symptoms are often triggered by consumption of specific foods (which are unique in each sufferer).  The total cost (direct + indirect) of IBS has been estimated at $30 billion annually in the United States. IBS is a common condition that can substantially impair physical and mental well-being of a patient and a person’s ability to function both at home and in the workplace.